Marlow_Seed_Deck.pdf

The wordmark, one-line descriptor ("Practice software for physiotherapists. Scheduling, notes and billing in one place") and round details (Seed, EUR 1.2m, Spring 2026) are all present and legible, which is more than most covers deliver. What is missing is any geographic anchor or contact line, so a reader forwarding the deck cannot tell which market you serve or who to email.

The pain is concrete and quantified with primary research - 6 hours per week of admin per therapist and a 23-day average gap between visit and invoice, sourced from 38 practice interviews - which is exactly the evidence investors want instead of adjectives. The layout is cramped and the two headline stats collide with the body copy, so the strongest proof points are easy to miss.

Three well-chosen drivers - digital claim mandates by 2027, a generation of owners who reject desktop-era tools, and a slow-consolidating long tail - give a credible timing argument. None of the three carries a citation or a named regulation, so the most important claim (the 2027 digital mandate) currently reads as assertion rather than fact.

The "book, treat, note, bill" narrative maps cleanly onto the three problems from slide 2, and the UI mock with colour-coded status pills makes the product tangible rather than aspirational. The line "Live in 11 practices since March 2026" is buried at the bottom when it is the most valuable sentence on the slide.

The three pillars (setup in an afternoon, tablet-native note taking, insurer-ready invoice and claim formats for the Netherlands, Germany and Poland) frame a credible SMB wedge, and the Utrecht practice owner quote on Sunday invoicing is the strongest line on the slide. The slide asserts capability without a single product screenshot or a quantified time-saved number, so an investor cannot judge whether this is a real workflow product or a thin wrapper.

Six named practices across NL, PL and DE shows early multi-country pull, but a logo wall with zero revenue, retention, or usage metrics is not traction at seed - and the cards are text-only, so even the social proof lands weakly. Investors cannot tell if these are paying customers, pilots, or friendly design partners.

Pricing is refreshingly concrete: EUR 89 per practice per month up to 4 therapists, EUR 19 per extra therapist, 30-day trial, annual plans at two months free, plus payments as a 2027 second revenue line. At EUR 89/month the model needs CAC and payback evidence, since outbound calling (slide 10) is an expensive motion against roughly EUR 1,068 of annual contract value.

The curve from EUR 0.1m (2026) to EUR 18m (2030) is clearly plotted with break-even flagged in Year 3, but the stated assumptions are internally inconsistent - 40% year-on-year growth cannot produce EUR 0.9m to EUR 3.4m, which is roughly 280% - and no y-axis scale, cost base, or headcount plan is shown. That undermines confidence in every other number in the deck.

Three channels are named with a real proof point - four of the practices came from referral by another practice - and the expansion order (NL and Poland first on founder networks, Germany 2027) is sensibly justified. No channel is quantified: no calls-to-demo rate, demo-to-close rate, CAC, or signed association agreement, so this reads as a plan rather than a tested motion.

The "notes and billing to the practice's operating system" framing is a credible land-and-expand narrative, and sequencing NL/PL claim formats before German localisation shows commercial logic, but the slide is a feature list with years attached and no outcome metrics - nothing tells an investor what revenue, retention, or ACV each phase is supposed to unlock.

This is a clean, specific ask - €1.2m SAFE, €300k already committed by two Dutch healthcare angels, 18 months runway, six named hires, and a stated Series A trigger of Germany going live - which is exactly the structure investors want; the gap is that the use-of-funds chart shows percentages with no € amounts and the 400-practice goal has no revenue attached, so the round's sufficiency can't be tested.

The Marlow wordmark, tagline "Every practice, out of the paper age," founder email and Utrecht location are all present, which is the minimum a closing slide needs; it misses the chance to leave investors with the one number or proof point they should remember from the pitch.